• Kallyope presented new clinical and preclinical data on migraine drug candidate elismetrep at the American Headache Society meeting on June 4, 2026.
• A Phase 1 study found a new softgel version absorbed faster than the prior capsule, with similar overall exposure and tolerability.
• Modeling based on the Phase 1 results indicated the new formulation could improve response rates and speed onset of relief versus the earlier formulation.
• Preclinical work suggested elismetrep could add benefit when combined with existing acute migraine drugs, supporting combination-use potential.
• Phase 3 studies are expected to start in mid-2026, positioning elismetrep as a potential new acute migraine option if late-stage results hold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kallyope Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.